These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26227776)

  • 21. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations.
    Kamsri P; Koohatammakun N; Srisupan A; Meewong P; Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Prueksaaroon S; Leartsakulpanich U; Pungpo P
    SAR QSAR Environ Res; 2014; 25(6):473-88. PubMed ID: 24785640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
    Neckles C; Eltschkner S; Cummings JE; Hirschbeck M; Daryaee F; Bommineni GR; Zhang Z; Spagnuolo L; Yu W; Davoodi S; Slayden RA; Kisker C; Tonge PJ
    Biochemistry; 2017 Apr; 56(13):1865-1878. PubMed ID: 28225601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth.
    Chollet A; Mori G; Menendez C; Rodriguez F; Fabing I; Pasca MR; Madacki J; Korduláková J; Constant P; Quémard A; Bernardes-Génisson V; Lherbet C; Baltas M
    Eur J Med Chem; 2015 Aug; 101():218-35. PubMed ID: 26142487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.
    Argyrou A; Vetting MW; Blanchard JS
    J Am Chem Soc; 2007 Aug; 129(31):9582-3. PubMed ID: 17636923
    [No Abstract]   [Full Text] [Related]  

  • 27. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
    Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
    Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
    Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
    Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
    Kanetaka H; Koseki Y; Taira J; Umei T; Komatsu H; Sakamoto H; Gulten G; Sacchettini JC; Kitamura M; Aoki S
    Eur J Med Chem; 2015 Apr; 94():378-85. PubMed ID: 25778993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.
    Boyne ME; Sullivan TJ; amEnde CW; Lu H; Gruppo V; Heaslip D; Amin AG; Chatterjee D; Lenaerts A; Tonge PJ; Slayden RA
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3562-7. PubMed ID: 17664324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
    Khan AM; Shawon J; Halim MA
    J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA.
    Li HJ; Lai CT; Pan P; Yu W; Liu N; Bommineni GR; Garcia-Diaz M; Simmerling C; Tonge PJ
    ACS Chem Biol; 2014 Apr; 9(4):986-93. PubMed ID: 24527857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme.
    Martinelli LKB; Rotta M; Villela AD; Rodrigues-Junior VS; Abbadi BL; Trindade RV; Petersen GO; Danesi GM; Nery LR; Pauli I; Campos MM; Bonan CD; de Souza ON; Basso LA; Santos DS
    Sci Rep; 2017 Apr; 7():46696. PubMed ID: 28436453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
    Chollet A; Maveyraud L; Lherbet C; Bernardes-Génisson V
    Eur J Med Chem; 2018 Feb; 146():318-343. PubMed ID: 29407960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA.
    Lai CT; Li HJ; Yu W; Shah S; Bommineni GR; Perrone V; Garcia-Diaz M; Tonge PJ; Simmerling C
    Biochemistry; 2015 Aug; 54(30):4683-91. PubMed ID: 26147157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus.
    Wang H; Lu Y; Liu L; Kim SW; Hooker JM; Fowler JS; Tonge PJ
    Eur J Med Chem; 2014 Dec; 88():66-73. PubMed ID: 25217335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
    Shirude PS; Madhavapeddi P; Naik M; Murugan K; Shinde V; Nandishaiah R; Bhat J; Kumar A; Hameed S; Holdgate G; Davies G; McMiken H; Hegde N; Ambady A; Venkatraman J; Panda M; Bandodkar B; Sambandamurthy VK; Read JA
    J Med Chem; 2013 Nov; 56(21):8533-42. PubMed ID: 24107081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.
    Štular T; Lešnik S; Rožman K; Schink J; Zdouc M; Ghysels A; Liu F; Aldrich CC; Haupt VJ; Salentin S; Daminelli S; Schroeder M; Langer T; Gobec S; Janežič D; Konc J
    J Med Chem; 2016 Dec; 59(24):11069-11078. PubMed ID: 27936766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.